Price History
Feb 9, 2026 — Aug 20, 2026Investment Snapshot
- Trading 49% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 25.0% with 24.4% net margin
- Revenue growing at 14% annually
CareDx, Inc. - Common Stock (CDNA) is a Healthcare company operating in Services-Medical Laboratories, listed on the NASDAQ , with a market capitalisation of $1.5 billion . Key value metrics: P/E ratio 14.2, P/B ratio 3.55, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
CareDx, Inc. - Common Stock — Fundamental Analysis Summary
CareDx, Inc. - Common Stock (CDNA) is currently trading 49% above its Graham Number of $19.53, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 14.2x.
On financial health, CDNA shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 25.0% (sector average: -20.1%), and manageable leverage with a debt-to-equity ratio of 0.36.
StockPik's composite Value Score for CDNA is 79/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CDNA shows revenue growing at 14% year-over-year, with earnings declining at 141%.